Journal
REVUE NEUROLOGIQUE
Volume 174, Issue 6, Pages 419-428Publisher
MASSON EDITEUR
DOI: 10.1016/j.neurol.2018.03.012
Keywords
Multiple sclerosis; Treatment; Interferon; Glatiramer acetate; Fumarates; Teriflunomide
Categories
Ask authors/readers for more resources
Today, first-line treatments for multiple sclerosis include injectable immunomodulators some of which have been on the market for nearly 25 years - as well as teriflunomide and dimethyl fumarate, which are more recent, but have opened the way for oral treatments. These drugs are considered similar in effectiveness, and their safety and side-effect profiles are generally reassuring. These treatments have been associated with a reduction in radiological and clinical disease activity, and a positive effect on patient quality of life, especially when introduced early in the disease process. This article will discuss data on first-line treatments currently available in France, their effectiveness and safety, and their place in pediatric patients and in woman who plan to become pregnant. (C) 2018 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available